自身免疫炎症性风湿病患者接种SARS-CoV-2 mRNA疫苗后体液免疫应答的不同轨迹:基于组的轨迹分析
这项单中心回顾性队列研究纳入2021年2月1日至12月6日接种SARS-CoV-2疫苗的293例自身免疫炎症性风湿病患者,用基于组的轨迹模型分析第一至第五剂接种后的血清中和抗体滴度,识别出低应答(13例,4.4%)、中应答(122例,41.6%)和高应答(158例,54.0%)三条轨迹,阿巴西普使用是低应答的最强预测因素(OR 11.55,95%CI 2.27-58.82,p=0.0032)。
要点
- 293例患者中低应答占4.4%、中应答占41.6%、高应答占54.0%。
- 阿巴西普使用是低应答最强预测因素(OR 11.55,95%CI 2.27-58.82,p=0.0032)。
- 低应答者白细胞介素-6和B细胞激活因子等炎症介质升高。
核心结论
- 在自身免疫炎症性风湿病患者中识别出不同的抗体应答轨迹,包括一个尽管反复接种仍持续低体液免疫应答的亚组。
- 该研究强调需要制定考虑个体临床和免疫因素的个性化疫苗接种策略,以优化这一脆弱人群的保护。
研究设计与样本
- 单中心回顾性队列研究,纳入2021年2月1日至12月6日接种SARS-CoV-2疫苗的自身免疫炎症性风湿病患者293例。
- 采用基于组的轨迹模型分析第一至第五剂接种后的血清中和抗体滴度,并比较各应答组的临床特征和血清细胞因子水平。
主要发现
- 基于组的轨迹模型识别出三条应答轨迹:低应答组13例(4.4%)、中应答组122例(41.6%)、高应答组158例(54.0%)。
- 阿巴西普使用是低应答的最强预测因素(OR 11.55,95%CI 2.27-58.82,p=0.0032),也与中应答相关(OR 3.82,95%CI 1.18-12.29,p=0.025)。
- 中应答还与年龄较大(OR 2.31,95%CI 1.38-3.85,p=0.0014)、使用吗替麦考酚酯(OR 3.03,95%CI 1.02-8.97,p=0.045)、抗中性粒细胞胞质自身抗体相关性血管炎(OR 3.26,95%CI 1.29-8.19,p=0.012)和类风湿关节炎(OR 1.62,95%CI 1.02-8.97,p=0.048)相关,而系统性红斑狼疮呈负相关(OR 0.49,95%CI 0.26-0.95,p=0.035)。
- 低应答者表现出白细胞介素-6和B细胞激活因子等炎症介质升高。
临床怎么用
- 作者认为,需要制定考虑个体临床和免疫因素的个性化疫苗接种策略,以优化这一脆弱人群的保护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with autoimmune inflammatory rheumatic diseases (AIRDs) are at a high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data on the effects of multiple (>3) vaccine doses and their influencing factors are limited. Understanding antibody dynamics after repeated vaccinations is essential for optimising vaccination strategies. Therefore, this study characterised the antibody response trajectories against SARS-CoV-2 and explored key clinical and immunological determinants. METHODS: This single-centre retrospective cohort study included patients with AIRDs who received SARS-CoV-2 vaccinations between 1 February and 6 December 2021. Serum neutralising antibody titres from the first to fifth vaccinations were analysed using group-based trajectory modelling (GBTM). The clinical characteristics and serum cytokine levels were compared between the response groups. RESULTS: The study included 293 patients with AIRDs. Three response trajectories were identified via GBTM: low responders (n = 13, 4·4%), middle responders (n = 122, 41·6%), and high responders (n = 158, 54·0%). Abatacept use was the strongest predictor of a low response (odds ratio 11·55, [95% confidence interval 2·27-58·82], p = 0·0032) but was also associated with a middle response (3·82, [1·18-12·29], p = 0·025). A middle response was also linked to older age (2·31 [1·38-3·85], p = 0·0014), mycophenolate mofetil use (3·03 [1·02-8·97], p = 0·045), anti-neutrophil cytoplasmic autoantibody-associated vasculitis (3·26 [1·29-8·19], p = 0·012), and rheumatoid arthritis (1·62 [1·02-8·97], p = 0·048), while systemic lupus erythematosus was inversely associated (0·49 [0·26-0·95], p = 0·035). Low responders exhibited elevated inflammatory mediators, including interleukin-6 and B-cell activating factor. CONCLUSION: We identified distinct antibody response trajectories in patients with AIRDs, including a subgroup with persistently low humoral immune responses despite repeated vaccinations. This study highlights the need for personalised vaccination strategies that consider individual clinical and immunological factors to optimise protection in this vulnerable populations.
引用
- Yamaguchi Y, Amiya S, Inokuchi S, et al. Distinct trajectories of humoral immune responses after SARS-CoV-2 mRNA vaccination in autoimmune inflammatory rheumatic diseases: A group-based trajectory analysis. Vaccine. 2025. PMID: 41083320. doi:10.1016/j.vaccine.2025.127771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。